Johnson & Johnson’s MedTech performance rallies industry

Apr. 19, 2022 1:21 PM ETiShares U.S. Medical Devices ETF (IHI), ISRG, SYK, ZBHJNJ, BSX, GKOS, NARIBy: Dulan Lokuwithana, SA News Editor

Innovative and medical technology

bymuratdeniz/iStock via Getty Images

  • MedTech stocks are trading sharply higher on Tuesday after the industry bellwether Johnson & Johnson (JNJ) reported better than expected Q1 2022 sales for its MedTech segment.
  • The iShares U.S. Medical Devices ETF (NYSEARCA:IHI) has recorded the best intraday gain since June 2020, driven by notable gainers such as Intuitive Surgical (NASDAQ:ISRG), Stryker (NYSE:SYK), Boston Scientific (BSX), Glaukos Corporation (GKOS) and Inari Medical (NARI).
  • Revenue from J&J’s MedTech division, previously identified as Medical Devices, reached $7.0B for the quarter with a ~6% YoY growth, exceeding the Street forecasts of $6.7B, according to Bloomberg.
  • In reaction, Needham analyst Mike Matson wrote: “We believe JNJ’s MedTech results are a positive indicator and expect most of our companies under coverage to beat consensus estimates in 1Q22.”
  • Citing J&J’s (JNJ) MedTech sales, Wells Fargo’s Larry Biegelsen argued that orthopedic sales of Stryker (SYK) and Zimmer Biomet (NYSE:ZBH) could exceed estimates.
  • Since the COVID-driven slump in March 2020, both stocks have underperformed the broader market, as shown in this graph.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.